<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513630</url>
  </required_header>
  <id_info>
    <org_study_id>CCEMD002</org_study_id>
    <nct_id>NCT00513630</nct_id>
  </id_info>
  <brief_title>Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease</brief_title>
  <acronym>SPREADDIMCAD</acronym>
  <official_title>Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the recurrence risk of cardiovascular events in
      patients with type 2 diabetes mellitus and coronary heart disease after different
      antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized,
      parallel control and prospective study

      The end point of this study is:

        1. follow up 3yr

        2. recurrence of cardiovascular event

        3. death caused by other reasons such as stroke, uremia, blindness and amputation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>New or worsening angina</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new or worsening heart failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new critical cardiac arrhythmia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new peripheral vascular events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>glipizide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide</intervention_name>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>glipizide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary heart disease

          -  Type 2 diabetes

        Exclusion Criteria:

          -  Severe organ dysfunction, psychopathy, infection, neutropenia

          -  Congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Ning, MD. PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>April 25, 2011</last_update_submitted>
  <last_update_submitted_qc>April 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Shanghai Jiao Tong University School of Medicine</name_title>
    <organization>Shanghai Jiao Tong University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

